Is direct-to-consumer advertising appropriate when it comes to health information?
My my, the FDA have been busy recently. Or, perhaps more accurately, they have been publicly busy recently. As the primary agency involved in the regulation and supervision of food and pharmaceutical safety standards, the US Food and Drug Administration may not be the most glamorous of government bodies (FDA, Miami anyone?) but it certainly has its work cut out in an age where technological advances in the generation of health data are outpacing changes in law and policy.
We’re entering a very interesting era of health informatics. We now have the technology to collect, for relatively little cost, terabytes of data on an individual related to their genetics, metabolism, gut flora, immune response, brain activity… the list goes on. The question is – how can we use these data to make meaningful choices about healthcare? And should individuals without medical training, be allowed access to information about their own health status that could be misinterpreted or misused? This is the current subject of debate in the somewhat bizarre altercation between the FDA and 23andme – a company set up to provide (limited) genetic information direct to consumer (DTC).
Read More